• 首页期刊简介编委会刊物订阅专栏专刊电子刊学术动态联系我们English
引用本文:田丹丽,梁春坡.肺奴卡菌病药物治疗的研究进展[J].中国现代应用药学,2020,37(14):1783-1787.
TIAN Danli,LIANG Chunpo.Development of Drug Treatment for Pulmonary Nocardiosis[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(14):1783-1787.
【打印本页】   【HTML】   【下载PDF全文】   查看/发表评论  【EndNote】   【RefMan】   【BibTex】
←前一篇|后一篇→ 过刊浏览    高级检索
本文已被:浏览 10910次   下载 6529 本文二维码信息
码上扫一扫!
分享到: 微信 更多
肺奴卡菌病药物治疗的研究进展
田丹丽1, 梁春坡2
1.天津市第一中心医院, 天津 300192;2.天津医科大学总医院, 天津 300052
摘要:
肺奴卡菌病是由奴卡菌侵犯人体肺部所引起的急性或慢性化脓性或肉芽肿性疾病,是罕见的机会性感染疾病,常见于免疫缺陷人群。近十几年来随着免疫抑制宿主数量的增加,奴卡菌感染病例逐年增多,病死率较高,早期诊断及有效的治疗和定期监测是改善预后的关键。近年来对肺奴卡菌病治疗的研究有了一定的进展,本文就肺奴卡菌病的病原学及流行病学、临床表现、治疗最新进展予以综述,为临床合理用药提供参考。
关键词:  肺奴卡菌病  药物  治疗  复方磺胺甲噁唑
DOI:10.13748/j.cnki.issn1007-7693.2020.14.024
分类号:R969.3
基金项目:
Development of Drug Treatment for Pulmonary Nocardiosis
TIAN Danli1, LIANG Chunpo2
1.Tianjin First Central Hospital, Tianjin 300192, China;2.General Hospital of Tianjin Medical University, Tianjin 300052, China
Abstract:
Pulmonary nocardiosis is an acute or chronic, suppurative or granulomatous disease caused by nocardia invading the lungs of the human body. It is a rare opportunistic infection and is common in immunodeficiency populations. With the increase of the number of immunosuppressive hosts in the past decade, the number of cases of nocardia infection has increased year by year, and the mortality rate is high. Early diagnosis and effective treatment and regular monitoring are the key to improve the prognosis. In recent years, progress has been made in the research on the treatment of pulmonary nocardiosis. This article reviews the etiology, epidemiology, clinical manifestations and treatment progress of pulmonary nocardiosis to provide a reference for clinical rational drug use.
Key words:  pulmonary nocardiosis  drug  treatment  trimethoprim-sulfamethoxazole
扫一扫关注本刊微信